Prospective Clinical Evaluation of BD Spinal Needles
- Conditions
- AnesthesiaAnalgesia
- Registration Number
- NCT05214560
- Lead Sponsor
- Becton, Dickinson and Company
- Brief Summary
- Post-market, observational study to assess the real-world safety and efficacy of BD Spinal Needles used in an on-market fashion. 
- Detailed Description
- Single-arm, post-market, observational, prospective study of participants who will receive neuraxial procedures with a BD Spinal Needle as part of their routine medical care. 
 Patients will be followed from BD Spinal needle insertion up to 7 days after the insertion according to the routine medical care and site policy.
 Data collected will be gathered from the patient's medical charts.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 160
- Any patient, regardless of age or gender, for which the investigator has decided that a neuraxial procedure must be performed utilizing BD Spinal Needles as part of their routine medical care
- Expected to be available for observation through the study period (7-days post procedure)
- Provision of signed and dated informed consent form (Note: Consent of guardian or parent may be required for patients under the age of 18 years; participant assent may be required as well.)
- Undergoing emergency surgery
- Coagulopathy or bleeding disorder for which regional anesthesia poses an increased risk
- History of neurological impairment or disease of the trunk or lower extremities.
- Infection at or near the site of needle insertion
- Previous spine surgery at the level involved in the study procedure
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
- Name - Time - Method - Primary Safety: Incidence of Post-dural Puncture Headache (PDPH). - From insertion up to 7 days post procedure - Percentage of participants with a diagnosis of PDPH in the 7 days following the anesthesia procedure. - Primary Performance: Incidence of Successful Needle Placement - During the insertion procedure - Successful needle placement in the subarachnoid space defined as the appearance of cerebrospinal fluid from the spinal needle hub. 
- Secondary Outcome Measures
- Name - Time - Method - Secondary Safety: Incidence of Any Needle or Procedure-related Nerve Damage (Pain or Weakness Lower Extremities). - From insertion up to 7 days post procedure - Incidence of any device or procedure-related adverse events, including the incidence of any nerve damage (pain or weakness lower extremities). - Secondary Safety: Incidence of Any Needle or Procedure-related Pain, Skin Redness, Irritation at or Near the Skin Puncture Site. - From insertion up to 7 days post procedure - Incidence of device/procedure-related adverse events including the incidence of any pain, skin redness, irritation at or near the skin puncture site. - Secondary Safety: Incidence of Any Needle or Procedure-related Backache. - From insertion up to 7 days post procedure - Incidence of device/procedure-related adverse events including the incidence of backache. - Secondary Safety:Incidence of Any Needle or Procedure-related Spinal/Epidural Hematoma. - From insertion up to 7 days post procedure - Incidence of device/procedure-related adverse events including the incidence of any spinal/epidural hematoma. - Secondary Safety: Incidence of Any Needle or Procedure-related Infection (Meningitis, Spinal Abscess) - From insertion up to 7 days post procedure - Incidence of device/procedure-related adverse events including the incidence of any infection (meningitis, spinal abscess) 
Trial Locations
- Locations (6)
- Medizinische Universität Wien 🇦🇹- Wien, Austria - Sejnjoen Central Hospital 🇫🇮- Seinäjoki, Finland - Charité Campus Benjamin Franklin 🇩🇪- Berlin, Germany - Universitätsklinikum Leipzig 🇩🇪- Leipzig, Germany - Hospital Universitario Quirónsalud Madrid 🇪🇸- Madrid, Spain - Schulthess Klinik, Zürich 🇨🇭- Zürich, Switzerland Medizinische Universität Wien🇦🇹Wien, Austria
